These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16431306)

  • 21. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
    BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
    Geusens P; Alten R; Rovensky J; Sloan VS; Krammer G; Kralidis G; Richardson P
    Int J Clin Pract; 2004 Nov; 58(11):1033-41. PubMed ID: 15605667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
    Grifka JK; Zacher J; Brown JP; Seriolo B; Lee A; Moore A; Gimona A
    Clin Exp Rheumatol; 2004; 22(5):589-96. PubMed ID: 15485012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
    Moore RA; Derry S; Makinson GT; McQuay HJ
    Arthritis Res Ther; 2005; 7(3):R644-65. PubMed ID: 15899051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
    Ashcroft DM; Chapman SR; Clark WK; Millson DS
    Ann Pharmacother; 2001; 35(7-8):829-34. PubMed ID: 11485128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.
    Rostom A; Muir K; Dubé C; Jolicoeur E; Boucher M; Joyce J; Tugwell P; Wells GW
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):818-28, 828.e1-5; quiz 768. PubMed ID: 17556027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL
    Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.